查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813870

美国多体学市场规模、份额和趋势分析报告：按产品/服务、类型、平台、应用、最终用途和细分市场预测，2025 年至 2033 年

U.S. Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By Platform, By Application, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国多组体学市场摘要

预计 2024 年美国多组体学市场价值将达到 11.8 亿美元，到 2033 年将达到 43.6 亿美元，2025 年至 2033 年的复合年增长率为 15.58%。

这一显着增长是由个人化医疗需求的不断增长、人工智慧和机器学习在生物数据解读中的整合以及对全面疾病分析日益增长的需求所推动的。此外，政府和私营部门对研发的投资不断增加以及在药物发现、诊断和精准医疗领域的应用不断扩大预计将在预测期内进一步推动市场成长。

技术创新

体学平台和分析工具的快速技术创新是美国多体学产业的主要驱动力。高通量定序技术（例如次世代定序(NGS)）的突破，显着提高了基因组和转录组资料产生的速度和深度，同时降低了每个样本的成本。同样，质谱、层析法和成像技术的进步也显着提高了蛋白质体学和代谢体学研究的分辨率和灵敏度。这些技术创新使研究人员能够更详细、更准确地了解复杂的生物过程，这对于疾病研究、药物研发和精准诊断的应用至关重要。

强大的运算工具、云端基础平台和人工智慧主导的分析技术的进步彻底改变了多组体学资料的处理、整合和解读方式。这些技术能够无缝分析大型多层资料集，减少资料处理瓶颈，并加速洞察。因此，多组体学工作流程变得更加自动化、可扩展、经济高效，并且越来越容易被大型製药公司、中小型生物技术公司、学术机构和临床实验室所接受。这些技术进步的融合不仅将多体学的应用扩展到新的疾病领域，而且还透过普及多体学研究的途径加速了美国市场的成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析

第四章美国多组体学市场：产品与服务的商业分析

  • 细分仪表板
  • 美国多组体学市场产品与服务波动分析
  • 美国多组体学市场规模和趋势分析（按产品/服务，2021-2033 年）
  • 产品
  • 服务

第五章美国多组体学市场：类型业务分析

  • 细分仪表板
  • 美国多体学市场类型波动分析
  • 美国多组体学市场规模及趋势分析（按类型）（2021-2033）
  • 单细胞多组体学
  • 批量体学

第六章美国多组体学市场：平台业务分析

  • 细分仪表板
  • 美国多体学市场平台波动分析
  • 美国多体学市场规模与趋势分析（按平台，2021-2033）
  • 基因组学
  • 转录组学
  • 蛋白质体学
  • 代谢体学
  • 整合组体学平台

第七章美国多组体学市场：应用业务分析

  • 细分仪表板
  • 美国多组体学市场使用变化分析
  • 美国多体学市场规模与趋势分析（按应用，2021-2033）
  • 细胞生物学
  • 肿瘤学
  • 神经病学
  • 免疫学

第八章美国多组体学市场：最终用途业务分析

  • 细分仪表板
  • 美国多组体学市场最终用途差异分析
  • 美国多体学市场规模和趋势分析（按最终用途）（2021-2033）
  • 学术研究机构
  • 製药和生物技术公司
  • 其他的

第九章 竞争态势

  • 参与企业
  • 战略地图
  • 2024年企业市场分析
  • 参与企业概况
    • BD
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc
    • Danaher（Beckman Coulter）
    • PerkinElmer Inc.
    • Shimadzu Corporation
    • Bruker
    • QIAGEN
    • Agilent Technologies, Inc.
    • BGI Genomics
Product Code: GVR-4-68040-282-8

U.S. Multiomics Market Summary

The U.S. multiomics market size was estimated at USD 1.18 billion in 2024 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 15.58% from 2025 to 2033. This significant growth is driven by increasing demand for personalized medicine, the integration of artificial intelligence and machine learning in biological data interpretation, and the growing need for comprehensive disease profiling. Moreover, rising investments in research and development by both the government and private sectors and expanding applications in drug discovery, diagnostics, and precision healthcare are expected to propel market growth further over the forecast period.

Technological Innovations

The rapid pace of technological innovation across omics platforms and analytical tools is the key driver in the U.S. multiomics industry. Breakthroughs in high-throughput sequencing technologies, such as next-generation sequencing (NGS), have dramatically increased the speed and depth of genomic and transcriptomic data generation while reducing the cost per sample. Similarly, advancements in mass spectrometry, chromatography, and imaging technologies have significantly improved the resolution and sensitivity of proteomics and metabolomics studies. These innovations enable researchers to obtain a more detailed and accurate view of complex biological processes, essential for applications in disease research, drug discovery, and precision diagnostics.

The evolution of powerful computational tools, cloud-based platforms, and AI-driven analytics has revolutionized how multiomics data is processed, integrated, and interpreted. These technologies allow for the seamless analysis of large-scale, multi-layered datasets, reducing bottlenecks in data handling and accelerating insights. As a result, multiomics workflows are becoming more automated, scalable, and cost-effective, making them increasingly accessible to large pharmaceutical companies and smaller biotech firms, academic institutions, and clinical laboratories. The convergence of these technological advancements is not only expanding the application of multiomics across new disease areas. Still, it is also helping to democratize access to multiomics research, thereby accelerating the market's growth in the U.S.

U.S. Multiomics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. multiomics market report based on product & service, type, platform, application, and end use:

  • Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Products
    • Instruments
    • Consumables
    • Software
  • Services
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Single-cell Multiomics
  • Bulk Multiomics
  • Platform Outlook (Revenue, USD Million, 2021 - 2033)
  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Integrated Omics Platforms
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell Biology
  • Oncology
  • Neurology
  • Immunology
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service
    • 1.2.2. Type
    • 1.2.3. Platform
    • 1.2.4. Application
    • 1.2.5. End Use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological Innovation
      • 3.2.1.2. Advancements in precision medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Data integration and analytical complexity
      • 3.2.2.2. High cost of multiomics technologies and workflows
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Multiomics Market: Product & Service Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Multiomics Market Product & Service Movement Analysis
  • 4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
  • 4.4. Product
    • 4.4.1. Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Software
      • 4.4.4.1. Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Multiomics Market: Type Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Multiomics Market Type Movement Analysis
  • 5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Single-cell Multiomics
    • 5.4.1. Single-cell Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Bulk Multiomics
    • 5.5.1. Bulk. Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Multiomics Market: Platform Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Multiomics Market Platform Movement Analysis
  • 6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2021 to 2033 (USD Million)
  • 6.4. Genomics
    • 6.4.1. Genomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Transcriptomics
    • 6.5.1. Transcriptomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Proteomics
    • 6.6.1. Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Metabolomics
    • 6.7.1. Metabolomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Integrated Omics Platforms
    • 6.8.1. Integrated Omics Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Multiomics Market: Application Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Multiomics Market Application Movement Analysis
  • 7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 7.4. Cell Biology
    • 7.4.1. Cell Biology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Neurology
    • 7.6.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Immunology
    • 7.7.1. Immunology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Multiomics Market: End Use Business Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Multiomics Market End Use Movement Analysis
  • 8.3. U.S. Multiomics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.4. Academic and Research Institutes
    • 8.4.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Pharmaceutical & Biotechnology Companies
    • 8.5.1. Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Participant's Overview
    • 9.4.1. BD
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Illumina, Inc
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Danaher (Beckman Coulter)
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. PerkinElmer Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Shimadzu Corporation
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Bruker
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. QIAGEN
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Agilent Technologies, Inc.
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. BGI Genomics
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. multiomics market, by product & service, 2021 - 2033 (USD Million)
  • Table 4 U.S. multiomics market, by type, 2021 - 2033 (USD Million)
  • Table 5 U.S. multiomics market, by platform, 2021 - 2033 (USD Million)
  • Table 6 U.S. multiomics market, by application, 2021 - 2033 (USD Million)
  • Table 7 U.S. multiomics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Multiomics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. multiomics market driver analysis
  • Fig. 14 U.S. multiomics market restraint analysis
  • Fig. 15 U.S. multiomics market: Porter's analysis
  • Fig. 16 U.S. multiomics market: PESTEL analysis
  • Fig. 17 U.S. multiomics market: Product & service outlook and key takeaways
  • Fig. 18 U.S. multiomics market: Product & service market share analysis, 2024 - 2033
  • Fig. 19 U.S. multiomics by products market, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. multiomics by instruments market, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. multiomics by consumables market, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. multiomics by software market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. multiomics by services market, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Multiomics market: Type outlook and key takeaways
  • Fig. 25 U.S. Multiomics market: Type market share analysis, 2024 - 2033
  • Fig. 26 U.S. multiomics by single-cell multiomics market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. multiomics by bulk multiomics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Multiomics market: Platform outlook and key takeaways
  • Fig. 29 U.S. Multiomics market: Platform market share analysis, 2024 - 2033
  • Fig. 30 U.S. multiomics by genomics market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. multiomics by transcriptomics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. multiomics by proteomics market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. multiomics by metabolomics market, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. multiomics by integrated omics platforms market, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Multiomics market: Application outlook and key takeaways
  • Fig. 36 U.S. Multiomics market: Application market share analysis, 2024 - 2033
  • Fig. 37 U.S. multiomics by cell biology market, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. multiomics by oncology market, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. multiomics by neurology market, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. multiomics by immunology market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Multiomics market: End use outlook and key takeaways
  • Fig. 42 U.S. Multiomics market: End use market share analysis, 2024 - 2033
  • Fig. 43 U.S. multiomics by academic and research institutes market, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. multiomics by pharmaceutical & biotechnology companies market, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. multiomics by others market, 2021 - 2033 (USD Million)
  • Fig. 46 Key company categorization
  • Fig. 47 Company market positioning
  • Fig. 48 Market participant categorization
  • Fig. 49 Strategy framework